News Sentiment

CNMD sentiment intelligence

CONMED Corporation news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 65 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 38.48 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+13.7% over one week, +10.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

CONMED (NYSE:CNMD) Downgraded by Zacks Research to Strong Sell

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction 13.7% Price confirming higher
Trend fit Trend inactive 10.7% over four weeks
Fair value -41.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 41
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 12
Sector context 0

Sources

Coverage mix

Publishers
Market source 15
Stock Titan 8
simplywall.st 5
TradingKey 5
MarketBeat 4
Investing.com 4
TradingView 3
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 25
Analyst action 3
Macro sensitivity 2
Capital return 1
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 65
Investing.com Direct company coverage

Needham reiterates Hold on Conmed stock amid sale exploration

Needham has reiterated a Hold rating on Conmed (NYSE:CNMD) after reports surfaced that the medical device company is exploring a potential sale. The firm anticipates offers could come at a significant premium, citing Conmed's mid-single-digit growth, strong recurring revenue, and

Tone
Positive 63/100
Event
Earnings
Published
14 Jul 2026 11:03
Source
Investing.com
Yahoo! Finance Canada Direct company coverage

CONMED (CNMD) Stock Trades Up, Here Is Why

Shares of medical technology company CONMED (CNMD) jumped 9% after reports indicated the company is exploring a potential sale due to interest from private equity firms. This surge occurred despite a recent downgrade by BofA Securities due to concerns about future growth and revi

Tone
Positive 66/100
Event
Analyst action
Published
13 Jul 2026 22:30
Source
Yahoo! Finance Canada
Moomoo Direct company coverage

CONMED Up Over 10%, on Pace for Largest Percent Increase Since May 2025 -- Data Talk

CONMED Corporation (CNMD) experienced a significant stock surge, rising over 10% on Monday, putting it on track for its largest percentage increase since May 2025. The stock's trading volume also substantially increased, reaching over 2 million shares, compared to its 52-week ave

Tone
Positive 71/100
Event
Market update
Published
13 Jul 2026 16:42
Source
Moomoo
StocksToTrade Direct company coverage

CNMD Jumps As Conmed Weighs Sale After PE Interest

Conmed Corp. (CNMD) is exploring strategic alternatives, including a potential sale, following private equity interest, causing its stock to jump by over 9%. While the company has solid financials and product strength in minimally invasive surgery and orthopedics, its profitabili

Tone
Positive 70/100
Event
Market update
Published
12 Jul 2026 15:10
Source
StocksToTrade
TradingView Direct company coverage

Price to sales forward of CONMED Corporation – NYSE:CNMD

This article provides a brief financial data point for CONMED Corporation (NYSE: CNMD), specifically its price to sales forward metric. It appears to be a stub or a section of a larger financial data platform, indicating the period and value of this financial ratio without furthe

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 02:41
Source
TradingView
Investing.com Direct company coverage

Conmed shares jump on potential sale report

Shares of CONMED Corporation surged over 8% in after-hours trading after Bloomberg reported that the medical device company is exploring a potential sale. The report indicated that CONMED is evaluating its options following expressions of takeover interest.

Tone
Positive 77/100
Event
Market update
Published
10 Jul 2026 21:10
Source
Investing.com
MarketBeat Direct company coverage

CONMED (NYSE:CNMD) Upgraded at BMO Capital Markets

BMO Capital Markets upgraded CONMED (NYSE:CNMD) shares to a "hold" rating, despite a generally cautious sentiment from other analysts. The medical technology company recently reported better-than-expected quarterly results, exceeding EPS and revenue estimates, although sales saw

Tone
Positive 60/100
Event
Earnings
Published
10 Jul 2026 10:10
Source
MarketBeat
AD HOC NEWS Direct company coverage

CNMD stock holds steady as focus shifts to the business

CONMED Corp (CNMD) stock is holding steady, with investor focus primarily on its surgical devices business and procedure-driven demand rather than recent headlines. The company, a US-listed medical technology name, specializes in equipment for operating rooms and minimally invasi

Tone
Neutral 50/100
Event
Macro sensitivity
Published
07 Jul 2026 16:31
Source
AD HOC NEWS
Ad-hoc-news.de Direct company coverage

CONMED stock centers on its medical device platform

CONMED Corp (CNMD) is a US-listed medical technology company specializing in surgical and orthopedic devices. Its business model relies on procedure-based demand and recurring hospital use, with revenue tied to procedure volumes and hospital budgets. The stock trades on Nasdaq an

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 21:10
Source
Ad-hoc-news.de
Market source Direct company coverage

CONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 2026

CONMED Corporation (NYSE: CNMD) announced that it will release its second quarter 2026 financial results after market close on Wednesday, July 29, 2026. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results. Interested parties can pre-regi

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 07:05
Source
Market source
Stock Titan Direct company coverage

Director Jeffrey Mirviss granted 5,603 RSUs at CONMED (NYSE: CNMD)

CONMED Corp director Jeffrey B. Mirviss was granted 5,603 restricted stock units (RSUs), which represent a contingent right to receive one share of common stock per RSU. These RSUs were awarded under the company's 2025 Long-Term Incentive Plan and are set to vest 100% after one y

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 23:10
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 CONMED Corporation For: 2 July By Investing.com

This article announces the publication of a Form 4 for CONMED Corporation on July 2nd. The content primarily consists of navigation links and market data, with the core informational part being the Form 4 announcement itself.

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:40
Source
Investing.com Canada
Stock Titan Direct company coverage

Director at CONMED (CNMD) receives grant of 5,603 restricted stock units

CONMED Corp director Celine Christine Martin was granted 5,603 restricted stock units (RSUs) as equity compensation, with each RSU representing a contingent right to receive one share of CONMED common stock. The RSUs were awarded at $0.00 per unit under the company’s 2025 Long-Te

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:40
Source
Stock Titan
Stock Titan Direct company coverage

New CONMED (CNMD) director Celine Christine Martin reports no common stock holdings

CONMED Corp's new director, Celine Christine Martin, has filed an initial Form 3 reporting no direct holdings of the company's common stock. She became a director on July 1, 2026, and this filing establishes a baseline for tracking any future changes in her ownership. The Form 3

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

New CONMED (CNMD) director Jeffrey Mirviss reports no common stock holdings

CONMED Corp director Jeffrey B. Mirviss, who joined the board on July 1, 2026, has filed an initial insider ownership report (Form 3). The filing indicates that Mirviss holds 0 shares of the company's Common Stock, thus reporting no beneficial ownership at this time. This report

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

CONMED schedules Q2 results call for July 29 after market close

CONMED Corporation (NYSE: CNMD) announced it will report its Q2 2026 financial results after the market closes on Wednesday, July 29, 2026. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results. Interested parties can pre-regis

Tone
Neutral 50/100
Event
Earnings
Published
02 Jul 2026 19:40
Source
Stock Titan
TradingView Direct company coverage

CNMD Forecast — Price Target — Prediction for 2027

The article provides a forecast and price target for CONMED Corporation (CNMD) stock, according to analyst opinions. It highlights the current stock price, recent performance, key financial metrics like revenue, earnings, and market capitalization, along with historical price dat

Tone
Negative 40/100
Event
Earnings
Published
01 Jul 2026 13:10
Source
TradingView
Yahoo! Finance Canada Direct company coverage

Why CONMED (CNMD) Shares Are Falling Today

CONMED (NYSE:CNMD) shares fell 4.9% after BofA Securities downgraded the stock to Underperform from Neutral, citing concerns about future growth and lowering its 2027 organic growth and EPS estimates. The firm maintained a $40.00 price target. This follows an earlier drop linked

Tone
Negative 27/100
Event
Analyst action
Published
29 Jun 2026 22:09
Source
Yahoo! Finance Canada
Investing.com Direct company coverage

BofA downgrades Conmed stock rating on growth concerns

BofA Securities has downgraded Conmed (NYSE:CNMD) to Underperform from Neutral, maintaining a $40 price target due to concerns over future growth. The firm lowered its 2027 organic growth estimate to 4.5% and its 2027 earnings per share estimate to $4.54, below consensus. BofA ex

Tone
Negative 30/100
Event
Analyst action
Published
29 Jun 2026 11:40
Source
Investing.com